Prostate cancer biomarkers: Current status

Kurt B. Hodges, Emily Bachert, Liang Cheng

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

Prostate cancer (PCa) is the second most frequently diagnosed cancer among men worldwide. Given the biological heterogeneity in localized PCa and its variable clinical course, a personalized approach to patient risk stratification and management is needed. A variety of high-throughput technologies, such as next-generation sequencing, transcriptomic, epigenetic, and metabolomic modalities have led to an improved understanding of the genomic basis of PCa and the identification of PCa biomarkers. Novel genomic approaches offer additional information to improve clinical decision making. The goal of this report is to review the use of currently available molecular biomarkers in the diagnosis and prognostication of PCa outcome.

Original languageEnglish (US)
Pages (from-to)353-369
Number of pages17
JournalCritical Reviews in Oncogenesis
Volume22
Issue number5-6
DOIs
StatePublished - Jan 1 2017

Keywords

  • DNA
  • Epigenetic signature
  • Gene panel
  • Metabolomics
  • Prostate cancer
  • Proteomics
  • RNA

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Prostate cancer biomarkers: Current status'. Together they form a unique fingerprint.

Cite this